Fine needle aspiration cytopathology of eccrine spiradenoma

Satturwar, Swati; Wakely, Paul E.; Limbach, Abberly Lott

doi:10.1016/j.jasc.2022.05.002

Cited by 4 publications

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Histopathological analysis is required to confirm the diagnosis and can be difficult. Indeed, while high-grade carcinomas present an abrupt transition between benign spiradenoma and spiradenocarcinoma areas, lower-grade carcinomas can present a similar appearance and necessitate ancillary tests such as immunohistochemical staining for Ki-67, p53, and S100 [3,7,8]. MRI and FDG PET-CT are recommended imaging modalities for tumor staging [3,9,10].…”

Section: Introductionmentioning

confidence: 99%

Spiradenocarcinoma: SEER Study of Epidemiology, Survival, and Treatment Options

Martineau

Walz

Scampa

et al. 2023

JCM

View full text Add to dashboard Cite

(1) Background: Spiradenocarcinoma is an extremely rare malignant adnexal tumor and there are only few studies on survival outcomes. Our aim was to perform an analysis of the demographic and pathological characteristics, treatment patterns, and survival outcomes of patients affected by spiradenocarcinoma. (2) Methods: The Surveillance, Epidemiology, and End Results program database of the National Cancer Institute was searched for all cases of spiradenocarcinoma diagnosed between 2000 and 2019. This database is considered representative of the US population. Demographic, pathological, and treatment variables were retrieved. Overall and disease-specific survival were computed according to the different variables. (3) Results: 90 cases of spiradenocarcinoma (47 females, 43 males) were identified. Mean age at diagnosis was 62.8 years. Regional and distant disease at diagnosis were rare, occurring in 2.2% and 3.3% of cases, respectively. Surgery alone was the most frequent treatment (87.8%), followed by a combination of surgery and radiotherapy (3.3%) and radiation therapy only (1.1%). Five-year overall survival was 76.2% and five-year disease-specific survival was 95.7%. (4) Conclusions: Spiradenocarcinoma equally affects males and females. Regional and distant invasion rates are low. Disease-specific mortality is low and is probably overestimated in the literature. Surgical excision remains the main form of treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Spiradenocarcinoma: SEER Study of Epidemiology, Survival, and Treatment Options

Martineau

Walz

Scampa

et al. 2023

JCM

View full text Add to dashboard Cite

show abstract

Solitary reddish–blue nodule with telangiectasia on the face

Vollmer,

Bertlich,

Haenssle

2023

Dermatologie

View full text Add to dashboard Cite

Cutaneous eccrine spiradenoma: Insights into cytomorphological features via fine needle aspiration biopsy and a comprehensive literature review

Shaker,

Vohra,

et al. 2023

Cytopathology

View full text Add to dashboard Cite

Eccrine spiradenoma (ES) is an uncommon and benign adnexal tumour originating from sweat glands. The cytological examination of ES poses a diagnostic challenge, as it can be mistaken for various benign and malignant basaloid skin neoplasms. The cytomorphologic features of ES are infrequently documented in existing literature. This study seeks to present a thorough exploration of the cytomorphologic traits associated with ES, accompanied by an analysis of ancillary testing that contribute to the accurate identification of this entity in cytological specimens.Eccrine spiradenoma is infrequently encountered in fine needle aspiration (FNA) cytopathology, and the available literature on its cytomorphologic features is limited. The challenge arises from its similarity to other benign and malignant dermal basaloid neoplasms, emphasizing the critical role of clinicopathologic correlation and immunohistochemical staining in achieving a precise diagnosis.

show abstract

Fine needle aspiration cytopathology of eccrine spiradenoma

Cited by 4 publications

References 18 publications

Spiradenocarcinoma: SEER Study of Epidemiology, Survival, and Treatment Options

Spiradenocarcinoma: SEER Study of Epidemiology, Survival, and Treatment Options

Solitary reddish–blue nodule with telangiectasia on the face

Cutaneous eccrine spiradenoma: Insights into cytomorphological features via fine needle aspiration biopsy and a comprehensive literature review

Contact Info

Product

Resources

About